JP2005538034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005538034A5 JP2005538034A5 JP2003550745A JP2003550745A JP2005538034A5 JP 2005538034 A5 JP2005538034 A5 JP 2005538034A5 JP 2003550745 A JP2003550745 A JP 2003550745A JP 2003550745 A JP2003550745 A JP 2003550745A JP 2005538034 A5 JP2005538034 A5 JP 2005538034A5
- Authority
- JP
- Japan
- Prior art keywords
- kit
- dose
- administration
- formulated
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010002350 Interleukin-2 Proteins 0.000 claims 89
- 102000000588 Interleukin-2 Human genes 0.000 claims 89
- 230000003442 weekly effect Effects 0.000 claims 17
- 210000002966 serum Anatomy 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 10
- 238000011282 treatment Methods 0.000 claims 7
- 238000012423 maintenance Methods 0.000 claims 6
- 238000011284 combination treatment Methods 0.000 claims 5
- 210000000822 natural killer cell Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 4
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000055277 human IL2 Human genes 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1796801A | 2001-12-07 | 2001-12-07 | |
| US10/293,664 US20030185796A1 (en) | 2000-03-24 | 2002-11-12 | Methods of therapy for non-hodgkin's lymphoma |
| PCT/US2002/039253 WO2003049694A2 (en) | 2001-12-07 | 2002-12-06 | Methods of therapy for non-hodgkin's lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005538034A JP2005538034A (ja) | 2005-12-15 |
| JP2005538034A5 true JP2005538034A5 (https=) | 2006-11-30 |
Family
ID=26690566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550745A Withdrawn JP2005538034A (ja) | 2001-12-07 | 2002-12-06 | 非ホジキンリンパ腫の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1463524A4 (https=) |
| JP (1) | JP2005538034A (https=) |
| AU (1) | AU2002362098A1 (https=) |
| CA (1) | CA2469045A1 (https=) |
| WO (1) | WO2003049694A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| PL1631313T3 (pl) | 2003-06-05 | 2015-08-31 | Genentech Inc | Terapia skojarzona zaburzeń z komórek B |
| US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| MXPA06007236A (es) * | 2003-12-22 | 2006-08-31 | Chiron Corp | Uso de polimorfismos de receptor fc como diagnosticos para estrategias de tratamiento para trastornos de la respuesta inmune. |
| BRPI0511187A (pt) | 2004-05-20 | 2007-12-04 | Zymogenetics Inc | método para tratar cáncer em um indivìduo |
| TW201422238A (zh) | 2004-06-04 | 2014-06-16 | Genentech Inc | Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品 |
| JP2008530232A (ja) * | 2005-02-15 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 化学療法剤、ｉｌ−２および場合により抗ｃｄ２０抗体の組み合わせを使用してリンパ腫を処置する方法 |
| ATE460672T1 (de) | 2005-05-20 | 2010-03-15 | Genentech Inc | Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| WO2007062090A2 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| KR20190140090A (ko) | 2007-07-09 | 2019-12-18 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
| EP2200631A1 (en) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
| EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| ES2382058T3 (es) * | 2008-01-17 | 2012-06-04 | Philogen S.P.A. | Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| CN104059955A (zh) | 2009-08-11 | 2014-09-24 | 弗·哈夫曼-拉罗切有限公司 | 在无谷氨酰胺的细胞培养基中的蛋白质生产 |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| MX391086B (es) | 2015-06-24 | 2025-03-21 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
| NZ741067A (en) | 2015-10-02 | 2023-07-28 | Hoffmann La Roche | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
| CN115369086B (zh) * | 2022-02-22 | 2023-05-12 | 北京景达生物科技有限公司 | 一种nk细胞扩大培养的培养方案 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001247737A1 (en) * | 2000-03-24 | 2001-10-08 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2 |
-
2002
- 2002-12-06 JP JP2003550745A patent/JP2005538034A/ja not_active Withdrawn
- 2002-12-06 AU AU2002362098A patent/AU2002362098A1/en not_active Abandoned
- 2002-12-06 CA CA002469045A patent/CA2469045A1/en not_active Abandoned
- 2002-12-06 EP EP02797231A patent/EP1463524A4/en not_active Withdrawn
- 2002-12-06 WO PCT/US2002/039253 patent/WO2003049694A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005538034A5 (https=) | ||
| JP6878524B2 (ja) | Ｉｌ−１７抗体の医薬製品および安定した液体組成物 | |
| Motzer et al. | Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. | |
| De Bandt et al. | Tocilizumab for multirefractory adult-onset Still’s disease | |
| Semerano et al. | Developments with investigational Janus kinase inhibitors for rheumatoid arthritis | |
| CN100420482C (zh) | ω干扰素在制备用于治疗丙型肝炎的药物中的用途 | |
| Mori et al. | Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-naïve and experienced patients | |
| JP2006523682A5 (https=) | ||
| JP2003528155A5 (https=) | ||
| JP2014114288A5 (https=) | ||
| JP2023162351A (ja) | Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること | |
| CN120227453A (zh) | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 | |
| JP2018515493A5 (https=) | ||
| JP2025102888A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| KR20060023968A (ko) | 중증 급성 호흡기 증후군(ｓａｒｓ)의 치료를 위한 조성물및 방법 | |
| JP2020100653A (ja) | ベンラリツマブによる喘息症状の改善方法 | |
| EP3927729A1 (en) | Therapeutic antibody formulation | |
| JP2009515994A5 (https=) | ||
| Gensicke et al. | Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis | |
| JP7370357B2 (ja) | 医薬組成物 | |
| CN1946734B (zh) | 系统性治疗关节炎的组合物和方法 | |
| WO2021211927A1 (en) | Treatment of hidradenitis suppurativa | |
| AU2017363970A1 (en) | Methods of enhancing immune response with everolimus, dactolisib or both | |
| JPWO2021123902A5 (https=) | ||
| JP2005525317A5 (https=) |